All Updates

All Updates

icon
Filter
Product updates
Partnerships
AQEMIA achieves research milestone in collaborative research with Servier in immuno-oncology
AI Drug Discovery
Jun 28, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
AI Drug Discovery

AI Drug Discovery

Jun 28, 2024

AQEMIA achieves research milestone in collaborative research with Servier in immuno-oncology

Product updates
Partnerships

  • AI-driven drug developer AQEMIA has announced a notable breakthrough in its joint research partnership with pharmaceutical company Servier. The company's study has identified molecules effective toward an undruggable target in immuno-oncology. This achievement will grant AQEMIA a milestone payment of an undisclosed amount.

  • The partnership was initiated in December 2021 to accelerate drug discovery in immuno-oncology using AQEMIA’s cutting-edge AI technology and deep physics. The company conducts research for several internal therapeutic programs in relevant fields such as oncology, immunology, inflammation, and neurological disorders.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.